KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Retained Earnings: 2009-2025

Historic Retained Earnings for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to -$569.9 million.

  • Jazz Pharmaceuticals' Retained Earnings fell 160.87% to -$569.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$569.9 million, marking a year-over-year decrease of 160.87%. This contributed to the annual value of $1.1 billion for FY2024, which is 28.30% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Retained Earnings stood at -$569.9 million for Q3 2025, which was down 17.32% from -$485.8 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Retained Earnings' 5-year high stood at $1.3 billion during Q1 2021, with a 5-year trough of -$1.6 billion in Q3 2022.
  • For the 3-year period, Jazz Pharmaceuticals' Retained Earnings averaged around -$157.4 million, with its median value being -$569.9 million (2025).
  • Per our database at Business Quant, Jazz Pharmaceuticals' Retained Earnings slumped by 286.89% in 2022 and then soared by 217.27% in 2025.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Retained Earnings stood at $830.2 million in 2021, then plummeted by 235.57% to -$1.1 billion in 2022, then soared by 178.07% to $878.7 million in 2023, then grew by 28.30% to $1.1 billion in 2024, then plummeted by 160.87% to -$569.9 million in 2025.
  • Its Retained Earnings stands at -$569.9 million for Q3 2025, versus -$485.8 million for Q2 2025 and $1.0 billion for Q1 2025.